Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relat

This report is an essential source for data, analysis and strategic insight into Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships. The report provides key information relating to market share by sector and country. The report examines company’s business structure and operations, history and products, and provides an analysis of its key revenue lines.

Bharat Book.com announces the arrival of a new report, Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships

(http://www.bharatbook.com/detail.asp?id=83625)



In recent years, alliances between pharma and biotech companies have become common, with hundreds of relationships currently in place for drug developments across virtually all high priority conditions. Such alliances are of significant benefit to pharma companies who are aiming to combat the increasing need for new product development and rapidly escalating R&D costs. For biotechs, alliances provide crucial funding that can help to maintain and expand R&D activities. These synergistic benefits have resulted in over 30% of drugs in clinical trials now being a direct product of pharma-biotech alliances. However, poor deal structure and implementation continue to contribute to the failure of almost half of these relationships. ‘Successful Pharma-Biotech Alliance Strategies’ is a new report that examines the current landscape for pharma-biotech alliances and provides an in-depth analysis of the underlying factors that can determine their success or failure. Recent major joint ventures, acquisitions and licensing deals are evaluated and the latest trends and developments affecting alliance management are assessed. This report also performs a detailed examination of 9 case studies that profile varying approaches to deal structuring and relationship management, in addition to charting the current and future alliance activities of the top ten pharmaceutical companies. Volume and value forecasts for pharma-biotech deals to 2015 are also provided. Improve the effectiveness of your alliance strategies with this report’s detailed examination of the key issues influencing the success of relationships and a case study analysis of major recent alliances.




Table of Contents :

Successful Pharma-Biotech Alliance Strategies
Executive summary
Pharma and biotech company synergies
Overview of pharma-biotech alliances
Why pharma-biotech alliances fail
Strategies to manage pharma-biotech alliances
The future of pharma-biotech alliance management


Chapter 1 Pharma and biotech company

synergies
Summary
Background
The pharmaceutical industry
The research and development process
Resources
Constraints and pressures
The biotechnology industry
The research and development process
Resources
Constraints and presures
Drug development today
More sophisticated science
More complicated disease targets
Rapidly escalating costs
Declining R&D productivity

Conclusions



Chapter 2 Overview of pharma- biotech

alliances
Summary
Introduction
Evolution of major alliances
Genentech
ImClone
MedImmune
Current deal trends
Types of relationships currently undertaken
Licensing
Significant recent pharma-biotech licensing deals
Joint ventures
Significant recent pharma-biotech joint ventures
Acquisitions
Significant recent pharma-biotech acquisitions
Hostile takeovers
Offshore alliances
Japan
China
India
Canada
Number and value of alliances
Key therapeutic areas for pharma-biotech alliances

Conclusions

Chapter 3 Why pharma-biotech alliances fail

Summary
High failure rates
Symptoms of alliance failure
Factors that do not affect alliance success
Main causes of alliance failure
Management changes
Culture
Project organization and expectations
Alliance goals
Incentives
Roles and responsibilities
Sharing of business processes
Decision support infrastructure
Project and alliance leadership
Harmonization of information technology
Timelines and budgets
Alliance expectations
Other preventable problems
Technology failure
The drug approval process
Drug development success rates
Case study: Alza and Scios
Vulnerability by alliance type
Licensing deals
Joint ventures
Acquisitions

Conclusions




For further information, kindly visit:
http://www.bharatbook.com/detail.asp?id=83625


Or contact us at:
Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54,
CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

About Bharatbook.com:
Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help into and support critical, timely business decisions and strategies.
This article is free for republishing
Source: http://www.financealley.com/article_667568_15.html